VRDN · Viridian Therapeutics, Inc.\DE
Market Cap
$2.61B
Shares
113.29M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-06 | — | |
| 10-Q | 2026-08-06 | 2026-06-30 | |
| 8-K | 2026-06-29 | 2026-06-26 | |
| Investor Event Transcript | 2026-06-09 | 2026-06-30 | |
| 8-K | 2026-06-03 | 2026-06-02 | |
| Investor Event Transcript | 2026-06-03 | 2026-06-30 | |
| 8-K | 2026-05-28 | 2026-05-27 | |
| 8-K | 2026-05-26 | 2026-05-24 | |
| 8-K | 2026-05-11 | 2026-05-06 | |
| 8-K | 2026-05-05 | — | |
| 10-Q | 2026-05-05 | 2026-03-31 | |
| 8-K | 2026-05-05 | — | |
| DEF 14A | 2026-04-17 | 2026-06-02 | |
| 8-K | 2026-03-30 | — | |
| 8-K | 2026-02-26 | — | |
| 10-K | 2026-02-26 | 2025-12-31 | |
| 10-Q | 2025-11-05 | 2025-09-30 | |
| 8-K | 2025-11-05 | — | |
| 8-K | 2025-10-23 | 2025-10-21 | |
| 8-K | 2025-10-21 | — | |
| 8-K | 2025-10-20 | 2025-10-17 | |
| 10-Q | 2025-08-06 | 2025-06-30 | |
| 8-K | 2025-08-06 | — | |
| 8-K | 2025-07-30 | — | |
| 8-K | 2025-06-24 | 2025-06-20 | |
| 8-K | 2025-05-20 | — | |
| 8-K | 2025-05-06 | — | |
| 10-Q | 2025-05-06 | 2025-03-31 | |
| DEF 14A | 2025-04-25 | 2025-06-20 | |
| 8-K | 2025-04-07 | 2025-04-02 | |
| 8-K | 2025-03-10 | 2025-03-05 | |
| 8-K | 2025-03-04 | 2025-03-03 | |
| 10-K | 2025-03-03 | 2024-12-31 | |
| 8-K | 2025-02-27 | — | |
| 8-K | 2025-01-10 | 2025-01-07 | |
| 8-K | 2024-12-16 | — | |
| 10-Q | 2024-11-12 | 2024-09-30 | |
| 8-K | 2024-11-12 | — | |
| 8-K | 2024-09-12 | 2024-09-11 | |
| 8-K | 2024-09-10 | — | |
| 10-Q | 2024-08-08 | 2024-06-30 | |
| 8-K | 2024-08-08 | — | |
| 8-K | 2024-07-15 | — | |
| 8-K | 2024-06-20 | 2024-06-17 | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| 8-K | 2024-05-08 | — | |
| DEF 14A | 2024-04-26 | 2024-06-17 | |
| 8-K | 2024-04-16 | 2024-04-10 | |
| 8-K | 2024-02-27 | — | |
| 10-K | 2024-02-27 | 2023-12-31 |
Showing 1–50 of 134 filings
Key facts
CIK
1590750
CUSIP
92790C104
13F (30d)
196 filings
190 filers
Visit website
Investor relations